Shenzhen Salubris Pharmaceuticals Co., Ltd. Report of the Board of Directors' Audit Committee on the Supervision of the 2025 Annual Audit Accountant
In accordance with the "Company Law of the People's Republic of China," the "Administrative Measures for Independent Directors of Listed Companies," the "Rules Governing the Listing of Stocks on the Shenzhen Stock Exchange," the "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guide No. 1 - Normative Operation of Main Board Listed Companies," and the "Administrative Measures for the Selection and Appointment of Accounting Firms by State-owned Enterprises and Listed Companies," as well as the "Articles of Association of Shenzhen Salubris Pharmaceuticals Co., Ltd.," the Audit Committee of the Board of Directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. (hereinafter referred to as the "Company") has diligently performed its duties. The report of the Audit Committee on its supervision of the accounting firm's performance in 2025 is as follows:
I. Basic Information of the 2025 Annual Audit Accounting Firm
(I) Institutional Information
Daixin was established in 1985 and converted into a special general partnership in March 2012. Its headquarters are located in Beijing, with its registered address at 22nd Floor, 1 ZhiChun Road, Haidian District, Beijing. Daixin has 33 branches nationwide and a branch in Hong Kong. In 2017, it initiated the establishment of the Daixin International Accounting Network, which currently has 48 member firms in countries including the United States, Canada, Australia, Germany, France, the United Kingdom, and Singapore. Daixin is one of the earliest accounting firms in China engaged in securities services, was among the first to obtain H-share audit qualifications, and has over 30 years of experience in securities business.